RNAi screen analysis of viral host genes
Reference | Disease | Gene | SNP ID | SNP | p-value | Virus |
---|---|---|---|---|---|---|
Reference | Disease | Gene | SNP ID | SNP | p-value | Virus |
20185149 | Schizophrenia | ACSM1 | 116285 | rs433598 | 3.00E-06 | RV |
18347602 | Schizophrenia | ACSM1 | 116285 | rs151222 | 6.00E-06 | RV |
23583979 | Heart rate | ACTN4 | 81 | rs11083475 | 2.00E-06 | RV |
22019778 | Leprosy | ADGB | 79747 | rs2275606 | 4.00E-14 | RV |
23704328 | Primary tooth development (number of teeth) | ADK | 132 | rs7924176 | 8.00E-16 | RV |
23989729 | Infantile hypertrophic pyloric stenosis | APOA1 | 335 | rs12721025 | 2.00E-10 | RV |
23894747 | Schizophrenia | ARHGAP31 | 57514 | rs17203055 | 5.00E-06 | RV |
22139419 | Platelet counts | ARVCF | 421 | rs1034566 | 3.00E-08 | RV |
21782286 | Aging (time to event) | ATCAY | 85300 | rs10412199 | 3.00E-06 | RV |
23160099 | Sagittal craniosynostosis | BBS9 | 27241 | rs10262453 | 6.00E-20 | RV |
23251661 | Obesity-related traits | BDP1 | 55814 | rs35131626 | 9.00E-06 | RV |
23251661 | Obesity-related traits | BICC1 | 80114 | rs11006263 | 7.00E-06 | RV |
21779176 | Restless legs syndrome | BTBD9 | 114781 | rs9357271 | 8.00E-22 | RV |
17634447 | Restless legs syndrome | BTBD9 | 114781 | rs3923809 | 1.00E-17 | RV |
17637780 | Restless legs syndrome | BTBD9 | 114781 | rs9296249 | 4.00E-18 | RV |
22554406 | Electroencephalographic traits in alcoholism | C11orf84 | 144097 | rs10897449 | 7.00E-06 | RV |
23568457 | Anorexia nervosa | CAMK1D | 57118 | rs75263140 | 6.00E-06 | RV |
23459443 | QT interval (interaction) | CAMK1D | 57118 | rs10906189 | 6.00E-06 | RV |
23251661 | Obesity-related traits | CAMK1D | 57118 | rs10906142 | 4.00E-06 | RV |
23251661 | Obesity-related traits | CAMK1D | 57118 | rs4750211 | 6.00E-07 | RV |
21123754 | Alzheimer's disease biomarkers | CCDC134 | 79879 | rs7364180 | 1.00E-06 | RV |
24162737 | Alzheimer's disease (late onset) | CD33 | 945 | rs3865444 | 3.00E-06 | RV |
18976728 | Alzheimer's disease | CD33 | 945 | rs3826656 | 6.00E-06 | RV |
23555300 | Response to anti-TNF treatment in rheumatoid arthritis | CD84 | 8832 | rs6427528 | 2.00E-06 | RV |
21685912 | Progressive supranuclear palsy | CD8B | 926 | rs6547705 | 1.00E-08 | RV |
23958962 | Cocaine dependence | CDK1 | 983 | rs2456778 | 5.00E-06 | RV |
23396134 | Refractive error | CHRNG | 1146 | rs1881492 | 5.00E-11 | RV |
19561606 | Kidney stones | CLDN14 | 23562 | rs219780 | 4.00E-12 | RV |
21983787 | Melanoma | CLPTM1L | 81037 | rs401681 | 3.00E-08 | RV |
19836008 | Lung adenocarcinoma | CLPTM1L | 81037 | rs31489 | 2.00E-10 | RV |
18978790 | Lung cancer | CLPTM1L | 81037 | rs402710 | 4.00E-06 | RV |
24105470 | Adiponectin levels | CMIP | 80790 | rs2925979 | 2.00E-10 | RV |
22158537 | Type 2 diabetes | CMIP | 80790 | rs16955379 | 3.00E-07 | RV |
22451204 | Parkinson's disease | CNKSR3 | 154043 | rs2275336 | 9.00E-07 | RV |
23362303 | Stearic acid (18:0) plasma levels | CNN3 | 1266 | rs860873 | 2.00E-14 | RV |
18369459 | Psoriasis | COG6 | 57511 | rs7993214 | 2.00E-06 | RV |
22610502 | Immune reponse to smallpox (secreted IL-12p40) | COL1A2 | 1278 | rs3736638 | 3.00E-07 | RV |
17903307 | Mean forced vital capacity from 2 exams | COL1A2 | 1278 | rs441051 | 2.00E-06 | RV |
20541252 | Vitamin D insufficiency | CYP2R1 | 120227 | rs10741657 | 3.00E-20 | RV |
24057671 | Tuberculosis | DCUN1D5 | 84259 | rs7947821 | 2.00E-06 | RV |
23449627 | Pubertal anthropometrics | DDX55 | 57696 | rs786425 | 3.00E-06 | RV |
24101674 | Type 2 diabetes | DNER | 92737 | rs1861612 | 7.00E-08 | RV |
23284291 | Pulmonary function (interaction) | DNER | 92737 | rs7594321 | 3.00E-09 | RV |
23251661 | Obesity-related traits | EFNA1 | 1942 | rs11264330 | 5.00E-06 | RV |
21079520 | Non-small cell lung cancer | EIF4E2 | 9470 | rs1656402 | 8.00E-08 | RV |
23568457 | Eating disorders | EMP2 | 2013 | rs2221433 | 5.00E-06 | RV |
23319000 | Metabolite levels (MHPG) | EMP2 | 2013 | rs6498068 | 6.00E-06 | RV |
20732626 | Attention deficit hyperactivity disorder | EMP2 | 2013 | rs11074889 | 7.00E-07 | RV |
18464913 | Protein quantitative trait loci | EPS8 | 2059 | rs17415853 | 7.00E-07 | RV |
21738478 | White blood cell types | ERG | 2078 | rs7275212 | 2.00E-18 | RV |
23381943 | End-stage coagulation | F13A1 | 2162 | rs5985 | 3.00E-186 | RV |
23381943 | End-stage coagulation | F13A1 | 2162 | rs3024321 | 8.00E-142 | RV |
21116278 | MRI atrophy measures | F13A1 | 2162 | rs749005 | 3.00E-07 | RV |
23300138 | Tumor biomarkers | FAM3B | 54097 | rs441810 | 3.00E-22 | RV |
23824729 | Homocysteine levels | FANCA | 2175 | rs12921383 | 8.00E-11 | RV |
24204828 | Homeostasis model assessment of beta-cell function (interaction) | FAT3 | 120114 | rs7129229 | 1.00E-06 | RV |
20834067 | Longevity | GABRB3 | 2562 | rs3212335 | 1.00E-06 | RV |
19734545 | Cognitive performance | GABRB3 | 2562 | rs8043440 | 2.00E-06 | RV |
22139419 | Platelet counts | GP1BA | 2811 | rs6065 | 3.00E-11 | RV |
23251661 | Obesity-related traits | GRIA1 | 2890 | rs10065813 | 8.00E-06 | RV |
21658281 | Sudden cardiac arrest | GRIA1 | 2890 | rs12189362 | 3.00E-10 | RV |
20592726 | Asparaginase hypersensitivity in acute lymphoblastic leukemia | GRIA1 | 2890 | rs4958351 | 4.00E-07 | RV |
19260139 | Anthropometric traits | GRIA1 | 2890 | rs12658202 | 9.00E-06 | RV |
23251661 | Obesity-related traits | GRID2 | 2895 | rs7666831 | 8.00E-06 | RV |
24144296 | Axial length | GYLTL1B | 120071 | rs10838532 | 2.00E-06 | RV |
20397748 | Height | HHIP | 64399 | rs1812175 | 1.00E-09 | RV |
18391950 | Height | HHIP | 64399 | rs1492820 | 1.00E-11 | RV |
18391952 | Height | HHIP | 64399 | rs6854783 | 2.00E-09 | RV |
23417110 | Beta-2 microglubulin plasma levels | HLA-B | 3106 | rs2523608 | 9.00E-09 | RV |
22139419 | Platelet counts | HLA-B | 3106 | rs3819299 | 9.00E-10 | RV |
23534349 | QRS duration | HMCN1 | 83872 | rs13375391 | 9.00E-06 | RV |
21738484 | Bipolar disorder | HNRNPC | 3183 | rs17197037 | 2.00E-06 | RV |
23740937 | Systemic lupus erythematosus and Systemic sclerosis | ITGAM | 3684 | rs11860650 | 1.00E-10 | RV |
23273568 | Systemic lupus erythematosus | ITGAM | 3684 | rs9937837 | 7.00E-06 | RV |
21408207 | Systemic lupus erythematosus | ITGAM | 3684 | rs9888739 | 1.00E-15 | RV |
19165918 | Systemic lupus erythematosus | ITGAM | 3684 | rs11150610 | 2.00E-06 | RV |
20062063 | Electrocardiographic traits | KCNE1 | 3753 | rs727957 | 2.00E-12 | RV |
23870195 | Coronary artery calcification | KCNK13 | 56659 | rs4900022 | 4.00E-06 | RV |
23535732 | Prostate cancer | KCNN3 | 3782 | rs1218582 | 2.00E-08 | RV |
23251661 | Obesity-related traits | KCNN3 | 3782 | rs6691316 | 7.00E-06 | RV |
22544366 | Atrial fibrillation | KCNN3 | 3782 | rs6666258 | 2.00E-14 | RV |
20173747 | Atrial fibrillation | KCNN3 | 3782 | rs13376333 | 2.00E-21 | RV |
23870195 | Coronary artery calcification | KCNQ3 | 3786 | rs978152 | 8.00E-06 | RV |
20125193 | Cognitive performance | KIAA1217 | 56243 | rs2484873 | 4.00E-07 | RV |
24449572 | Rheumatoid arthritis | KIF5A | 3798 | rs1678542 | 1.00E-07 | RV |
21107309 | Reasoning | LYZL4 | 131375 | rs2286720 | 1.00E-06 | RV |
23251661 | Obesity-related traits | MATK | 4145 | rs12104221 | 3.00E-08 | RV |
23555189 | PCA3 expression level | MSMB | 4477 | rs10993994 | 1.00E-09 | RV |
22916037 | Metabolite levels | MYO1E | 4643 | rs2306786 | 1.00E-10 | RV |
24047820 | Social communication problems | MYO1E | 4643 | rs4218 | 1.00E-07 | RV |
23251661 | Obesity-related traits | NDUFA8 | 4702 | rs3818638 | 6.00E-06 | RV |
23969696 | Fibrinogen | NLRP3 | 114548 | rs10157379 | 1.00E-19 | RV |
23738518 | Word reading | NLRP3 | 114548 | rs10925015 | 8.00E-06 | RV |
21300955 | C-reactive protein | NLRP3 | 114548 | rs12239046 | 1.00E-15 | RV |
20031576 | Fibrinogen | NLRP3 | 114548 | rs1539019 | 1.00E-08 | RV |
23319000 | Metabolite levels (HVA/MHPG ratio) | NRXN1 | 9378 | rs6750634 | 4.00E-06 | RV |
22832960 | Temperament | NRXN1 | 9378 | rs6754640 | 1.00E-06 | RV |
20834067 | Longevity | NRXN1 | 9378 | rs1356888 | 1.00E-06 | RV |
20691247 | Personality dimensions | NRXN1 | 9378 | rs10176705 | 9.00E-06 | RV |
23263486 | Urate levels | NRXN2 | 9379 | rs478607 | 4.00E-11 | RV |
23319801 | Breast cancer (prognosis) | NTN1 | 9423 | rs3785982 | 8.00E-06 | RV |
18204098 | Systemic lupus erythematosus | NTNG2 | 84628 | rs11243676 | 3.00E-06 | RV |
21909109 | HDL cholesterol | OAS3 | 4940 | rs2072134 | 6.00E-06 | RV |
19136949 | Alzheimer's disease | PCDH11X | 27328 | rs2573905 | 2.00E-07 | RV |
23921680 | Allergic dermatitis (nickel) | PELI1 | 57162 | rs6733160 | 7.00E-06 | RV |
21221998 | Kawasaki disease | PELI1 | 57162 | rs7604693 | 2.00E-06 | RV |
24105470 | Adiponectin levels | PEPD | 5184 | rs889140 | 4.00E-12 | RV |
24097068 | HDL cholesterol | PEPD | 5184 | rs731839 | 3.00E-09 | RV |
22581228 | Fasting insulin-related traits (interaction with BMI) | PEPD | 5184 | rs8182584 | 9.00E-08 | RV |
22479202 | Adiponectin levels | PEPD | 5184 | rs4805885 | 2.00E-08 | RV |
22158537 | Type 2 diabetes | PEPD | 5184 | rs3786897 | 1.00E-08 | RV |
23251661 | Obesity-related traits | PHTF2 | 57157 | rs12234571 | 6.00E-06 | RV |
23251661 | Obesity-related traits | PKNOX2 | 63876 | rs7112365 | 2.00E-06 | RV |
22488850 | Alcohol and nictotine co-dependence | PKNOX2 | 63876 | rs1426153 | 2.00E-06 | RV |
21956439 | Alcohol dependence | PKNOX2 | 63876 | rs10893366 | 8.00E-06 | RV |
21703634 | Alcohol dependence | PKNOX2 | 63876 | rs750338 | 1.00E-06 | RV |
21298047 | Substance dependence | PKNOX2 | 63876 | rs12284594 | 7.00E-08 | RV |
19165232 | Panic disorder | PKP1 | 5317 | rs860554 | 5.00E-08 | RV |
23936387 | Celiac disease | PPP1R12B | 4660 | rs12734338 | 3.00E-07 | RV |
23251661 | Obesity-related traits | PPP1R12B | 4660 | rs12739262 | 1.00E-06 | RV |
20663923 | Autism | PPP2R5C | 5527 | rs7142002 | 3.00E-06 | RV |
17903302 | Tonometry | PREX1 | 57580 | rs6063312 | 2.00E-06 | RV |
21107309 | Reasoning | PRKCZ | 5590 | rs3753242 | 1.00E-06 | RV |
20881960 | Height | PRKCZ | 5590 | rs425277 | 2.00E-08 | RV |
18758461 | Chronic lymphocytic leukemia | PRKD2 | 25865 | rs11083846 | 4.00E-09 | RV |
23251661 | Obesity-related traits | PRKG1 | 5592 | rs293314 | 7.00E-06 | RV |
21907864 | Asthma | PRKG1 | 5592 | rs7922491 | 5.00E-07 | RV |
23472185 | Multiple sclerosis (OCB status) | PRKRA | 8575 | rs9283487 | 3.00E-07 | RV |
22566634 | Economic and political preferences (feminism/equality) | RAB30 | 27314 | rs11233413 | 4.00E-07 | RV |
23455636 | Age-related macular degeneration | RAD51B | 5890 | rs8017304 | 9.00E-11 | RV |
23001122 | Breast cancer (male) | RAD51B | 5890 | rs1314913 | 3.00E-13 | RV |
23118302 | Lipoprotein-associated phospholipase A2 activity change in response to statin therapy | RNF213 | 57674 | rs12051723 | 3.00E-06 | RV |
22589738 | Visceral adipose tissue/subcutaneous adipose tissue ratio | RPS14 | 6208 | rs13177918 | 8.00E-06 | RV |
21368711 | Personality dimensions | RXRG | 6258 | rs285480 | 4.00E-07 | RV |
21102462 | Menarche (age at onset) | RXRG | 6258 | rs466639 | 1.00E-13 | RV |
19754311 | AIDS | RXRG | 6258 | rs10800098 | 4.00E-06 | RV |
23535732 | Prostate cancer | SHROOM2 | 357 | rs2405942 | 2.00E-10 | RV |
22951594 | Breast cancer | SIAH2 | 6478 | rs6788895 | 9.00E-08 | RV |
21824976 | Bladder cancer | SLC14A1 | 6563 | rs7238033 | 9.00E-09 | RV |
21750109 | Bladder cancer | SLC14A1 | 6563 | rs17674580 | 8.00E-11 | RV |
23263486 | Urate levels | SLC17A1 | 6568 | rs1165151 | 7.00E-70 | RV |
21208937 | Iron levels | SLC17A1 | 6568 | rs17342717 | 5.00E-09 | RV |
20884846 | Urate levels | SLC17A1 | 6568 | rs1165196 | 5.00E-25 | RV |
19503597 | Uric acid levels | SLC17A1 | 6568 | rs1183201 | 3.00E-14 | RV |
19084217 | Iron status biomarkers | SLC17A1 | 6568 | rs17270561 | 5.00E-07 | RV |
22566634 | Economic and political preferences | SLC22A9 | 114571 | rs7101446 | 3.00E-06 | RV |
23202124 | Birth weight | SLC2A4 | 6517 | rs5415 | 5.00E-06 | RV |
23378610 | Metabolite levels | SLC6A12 | 6539 | rs499368 | 2.00E-10 | RV |
17903301 | Echocardiographic traits | SLIT2 | 9353 | rs1379659 | 1.00E-07 | RV |
17903301 | Echocardiographic traits | SLIT2 | 9353 | rs666088 | 5.00E-06 | RV |
20881960 | Height | SLIT3 | 6586 | rs4282339 | 7.00E-16 | RV |
24024966 | Periodontitis (Mean PAL) | SMURF2 | 64750 | rs111854052 | 9.00E-06 | RV |
22581228 | Fasting insulin-related traits (interaction with BMI) | SYN2 | 6854 | rs308971 | 2.00E-07 | RV |
24023261 | Lipid traits | THOC5 | 8563 | rs8135828 | 2.00E-07 | RV |
24025145 | Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel) | TMEM132C | 92293 | rs11059635 | 2.00E-07 | RV |
23456168 | Height | TMEM132C | 92293 | rs10773568 | 3.00E-06 | RV |
21423239 | Suicide attempts in bipolar disorder | TMEM132C | 92293 | rs7296262 | 1.00E-06 | RV |
23251661 | Obesity-related traits | TMEM229B | 161145 | rs17104363 | 5.00E-08 | RV |
22359512 | Phospholipid levels (plasma) | TMEM229B | 161145 | rs1077989 | 9.00E-18 | RV |
23251661 | Obesity-related traits | TMEM45B | 120224 | rs10894147 | 7.00E-06 | RV |
19721433 | Response to antipsychotic treatment | TRPM1 | 4308 | rs17815774 | 3.00E-06 | RV |
24024966 | Periodontitis (CDC/AAP) | WDR73 | 84942 | rs34069323 | 2.00E-06 | RV |